GlobalData on MSN9h
EU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLC
AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...
Daily16h
AstraZeneca Imfinzi based perioperative regimen recommended for approval in EU for resectable non-small cell lung cancer
AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...
PharmiWeb8h
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...
Pharmabiz13h
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...
Defence stocks hit record high: Shares soar as European leaders vow to boost military spending
Shares in FTSE 100 giants Rolls-Royce and BAE Systems soared to record highs after an emergency summit on Ukraine at the ...
Moneylife8h
Oversold Nifty, Sensex Dip on Massive US Tariffs : Tuesday Closing Report
On Tuesday, 2221 stocks advanced, 1737 declined and 128 remained unchanged, with an advance decline ratio of 1.28 on the ...
AstraZeneca (AZN) Receives a Buy from Bernstein
In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...
BALVERSA Adoption On The Rise: Meeting Unmet Needs In Advanced Urothelial Cancer | Delveinsight
BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...